$0.00 EPS Expected for United Health Products (UEEC); Eli Lilly & Company (LLY) Shorts Down By 6.72%

June 16, 2017 - By Darrin Black

Eli Lilly & Company (NYSE:LLY) had a decrease of 6.72% in short interest. LLY’s SI was 10.03M shares in June as released by FINRA. Its down 6.72% from 10.76M shares previously. With 3.48 million avg volume, 3 days are for Eli Lilly & Company (NYSE:LLY)’s short sellers to cover LLY’s short positions. The SI to Eli Lilly & Company’s float is 1.09%. The stock increased 0.55% or $0.45 on June 15, reaching $82.05. About shares traded. Eli Lilly and Co (NYSE:LLY) has risen 4.70% since June 16, 2016 and is uptrending. It has underperformed by 12.00% the S&P500.

Analysts expect United Health Products Inc (OTCMKTS:UEEC) to report $0.00 EPS on June, 21. The stock increased 2.98% or $0.0022 on June 15, reaching $0.0773. About shares traded. United Health Products Inc (OTCMKTS:UEEC) has 0.00% since June 16, 2016 and is . It has underperformed by 16.70% the S&P500.

Eli Lilly and Company is engaged in drug manufacturing business. The company has market cap of $91.03 billion. The Firm discovers, develops, makes and markets products in two divisions: human pharmaceutical products and animal health products. It has a 39.85 P/E ratio. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Since February 1, 2017, it had 0 insider buys, and 9 selling transactions for $59.49 million activity. Shares for $155,040 were sold by Zakrowski Donald A. Barnes Melissa S sold $153,482 worth of stock or 1,900 shares. $2.07M worth of Eli Lilly and Co (NYSE:LLY) was sold by Conterno Enrique A on Thursday, May 4. Harrington Michael J sold 22,833 shares worth $1.83M. Shares for $17.02M were sold by LILLY ENDOWMENT INC. Rice Derica W sold $861,085 worth of stock. $1.16M worth of Eli Lilly and Co (NYSE:LLY) was sold by Zulueta Alfonso G.

Among 17 analysts covering Eli Lilly and Company (NYSE:LLY), 13 have Buy rating, 1 Sell and 3 Hold. Therefore 76% are positive. Eli Lilly and Company had 49 analyst reports since July 23, 2015 according to SRatingsIntel. Jefferies maintained Eli Lilly and Co (NYSE:LLY) on Tuesday, April 11 with “Buy” rating. BMO Capital Markets upgraded Eli Lilly and Co (NYSE:LLY) on Monday, November 16 to “Outperform” rating. Bank of America maintained it with “Buy” rating and $108.0 target in Friday, September 18 report. Argus Research downgraded the stock to “Hold” rating in Thursday, April 27 report. The rating was maintained by Cowen & Co on Saturday, August 22 with “Outperform”. As per Tuesday, September 27, the company rating was upgraded by Goldman Sachs. Cowen & Co maintained Eli Lilly and Co (NYSE:LLY) on Monday, August 24 with “Outperform” rating. As per Wednesday, April 6, the company rating was initiated by Societe Generale. The stock has “Buy” rating by Jefferies on Thursday, July 14. The firm has “Outperform” rating given on Monday, May 2 by Leerink Swann.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: